Evidence Mapping of Proton Therapy, Heavy Ion Therapy, and Helical Tomotherapy for Gastric Cancer

Purpose: This study aimed to systematically present application situation and therapeutic effect of proton therapy (PT), heavy ion therapy, and helical tomotherapy (TOMO) for gastric cancer (GC), and to find gaps of existing studies. Methods: PubMed, EMBASE, the Cochrane Library, Web of Science, and Chinese Biological Medical Database were searched. Tables, bubble plot, and heat map were conducted to display results. Results: Fourteen studies were included. About PT, 7 single-arm studies showed median overall survival (OS) within 2–66 months and 1 study reported 40% of patients happened moderate degree of radiation gastritis. About TOMO, 1 study reported longer median OS and progression-free survival, lower occurrence of Grade III toxicity, and late toxicity compared to 3D-CRT, while another study remained neutral. About heavy ion therapy, there was no clinical study was found. Conclusions: Existing studies presented good clinic treatment effect about PT and TOMO for GC, and furthermore clinical studies are needed.

Download Full-text

Proton therapy for craniopharyngioma in adults: a protocol for systematic review and meta-analysis

BMJ Open ◽

10.1136/bmjopen-2020-046043 ◽

2021 ◽

Vol 11 (6) ◽

pp. e046043

Author(s):

Pengtao Li ◽

Jialing Wang ◽

Aximujiang Axier ◽

Kai Zhou ◽

Jingwei Yun ◽

...

Keyword(s):

Proton Therapy ◽

Ion Beam ◽

Grey Literature ◽

Intervention Group ◽

Heavy Ion ◽

Cochrane Library ◽

Secondary Outcome ◽

Significant Heterogeneity ◽

Recurrence Rates ◽

X Ray

IntroductionCraniopharyngioma is the most challenging to treat brain tumour with high recurrence rates, which can be effectively reduced by adjuvant radiotherapy. In recent years, proton therapy (PT), with its physical properties of heavy ion beam, that is, Prague peak phenomenon, has been more frequently used in patients with craniopharyngioma. Compared with conventional X-ray beam radiotherapy, PT can reduce the damage to normal tissues and enlarge the damage to tumours. Some studies have shown that PT has advantages in the treatment of craniopharyngioma in adults. However, the optimal management of craniopharyngioma remains controversial. The purpose of this study was to evaluate the efficacy and safety of PT for craniopharyngioma in adults.Methods and analysisWe will search six databases (MEDLINE, EMBASE, Web of Science, the Cochrane Library, Amed, Scopus), clinical research registration websites and grey literature, aiming to identify randomised controlled trials (RCTs) on PT for craniopharyngioma in adults between 1 January 1954 and 28 September 2021. In the RCTs, PT will be used as the intervention group, and conventional X-ray beam radiotherapy will be used as the comparator group. Tumour recurrence and survival will be the primary outcome, and treatment-related toxicity will be the secondary outcome. The study selection, data extraction, bias risk and quality evaluation will be operated by two to four researchers independently. We will use Review Manager V.5.2 (RevMan V.5.2) for data analysis. If there is significant heterogeneity, we will identify the source of heterogeneity by subgroup analysis.Ethics and disseminationOur study is based on existing RCTs and does not require ethical approval. The results of the study will be published in a peer-reviewed journal or at a related conference.PROSPERO registration numberCRD42020200909.

Download Full-text